Focus keyword: clia waived hematology analyzer
Theme: Regulation & Compliance
The label ’CLIA-waived’ is the most oversold phrase in point-of-care marketing, and on a blood analyzer it is usually a red flag, not a badge of honour.
CLIA waiver is reserved for tests so simple and error-resistant that the risk of erroneous results is negligible, and where failure poses no unreasonable risk of harm. A full 5-part differential CBC does not fit that definition: it demands sample prep, precise volumes, calibration and interpretive judgment. Most hematology analyzers are therefore moderate-complexity devices requiring a CLIA certificate of compliance and regular inspections. If a vendor pushes a ’waived’ CBC, read the exact test list on the FDA site before you believe it.
What counts as truly waived
Some extremely constrained single-parameter screens—certain hemoglobin-only devices with sample-containment systems—have earned waiver status under tight FDA conditions. That is a narrow niche, far removed from a five-parameter white-cell differential.
Why the distinction changes how you operate
A moderate-complexity analyzer brings QC requirements, competency assessment and inspection obligations. Budgeting for those from day one—rather than discovering them after an inspection—is the difference between a compliant POCT lab and a surprise citation.
How to verify a waiver claim
Search the FDA CLIA database by device name and intended use. If the analyzer’s exact model and claimed test panel is not on the published waived list, it is moderate complexity, full stop.
For a practical example in this space, see the portable multi-function blood analyzer.
Explore the RunMei diagnostic products.
Explore the contact our analyzer specialists.
As a next step, review the RunMei Health.
Why This Matters: Authoritative Context
Regulatory context is grounded in primary sources: the EU In Vitro Diagnostic Regulation 2017/746 (IVDR) defines the transition and classification duties the industry tracks, the U.S. FDA’s 510(k) and De Novo pathways govern US market access under 21 CFR Part 820, and ISO 15189 and ISO 13485 set the quality and laboratory-management benchmarks referenced throughout. For WHO Prequalification, the WHO In Vitro Diagnostics and Laboratory Technology programme publishes the specifications and performance requirements that prequalification assessments apply. Consulting these primary texts keeps a sourcing or validation decision honest and defensible.
